(vianews) - vistin pharma (vistn.ol) is among this list of stock assets with the highest dividend rate and return on equity on the drug manufacturers—specialty & generic industry.
| financial asset | price | forward dividend yield | return on equity |
|---|---|---|---|
| vistin pharma (vistn.ol) | kr24.30 | 3.13% | 16.03% |
| ipsen (ipn.pa) | €105.10 | 1.08% | 12.52% |
| vetoquinol (veto.pa) | €103.00 | 1.02% | 12.13% |
several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. vistin pharma (vistn.ol)
3.13% forward dividend yield and 16.03% return on equity
vistin pharma asa, through its subsidiary, vistin pharma as, produces and sells active pharmaceutical ingredients (apis) worldwide. it offers metformin hcl apis and direct compressive granulates for the pharmaceutical industry. the company was founded in 1969 and is headquartered in oslo, norway.
earnings per share
as for profitability, vistin pharma has a trailing twelve months eps of kr1.
pe ratio
vistin pharma has a trailing twelve months price to earnings ratio of 24.3. meaning, the purchaser of the share is investing kr24.3 for every norwegian krone of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 16.03%.
volatility
vistin pharma's last week, last month's, and last quarter's current intraday variation average was a negative 0.67%, a positive 0.10%, and a positive 1.90%.
vistin pharma's highest amplitude of average volatility was 1.71% (last week), 1.70% (last month), and 1.90% (last quarter).
revenue growth
year-on-year quarterly revenue growth grew by 30.8%, now sitting on 438.54m for the twelve trailing months.
more news about vistin pharma.
2. ipsen (ipn.pa)
1.08% forward dividend yield and 12.52% return on equity
ipsen s.a. operates as a biopharmaceutical company worldwide. the company provides drugs in the areas of oncology, neuroscience, and rare diseases. it offers somatuline for neuroendocrine tumors and acromegaly; dysport for motor muscular disorders and medical aesthetics; decapeptyl for the treatment of advanced metastatic prostate cancer; cabometyx for renal cell and second-line hepatocellular carcinoma; onivyde for second-line metastatic pancreatic cancer; and tazverik to treat third-line follicular lymphoma. the company also provides nutropinaq for growth failure in children due to growth hormone (gh) deficiency, turner syndrome or chronic renal insufficiency, and gh deficiency in adults; and increlex for growth failure in children and adolescents. in addition, it offers xermelo for the treatment of carcinoid syndrome; and cometriq to treat medullary thyroid cancer. ipsen s.a. has agreements with debiopharm; exelixis; galderma; blueprint medicines; tersera therapeutics; rhythm pharmaceuticals; teijin; schwabe; bakx therapeutics inc.; and exicure. the company was founded in 1929 and is headquartered in boulogne-billancourt, france.
earnings per share
as for profitability, ipsen has a trailing twelve months eps of €4.89.
pe ratio
ipsen has a trailing twelve months price to earnings ratio of 21.49. meaning, the purchaser of the share is investing €21.49 for every euro of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.52%.
revenue growth
year-on-year quarterly revenue growth grew by 8.4%, now sitting on 3.28b for the twelve trailing months.
stock price classification
according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ipsen's stock is considered to be oversold (<=20).
volatility
ipsen's last week, last month's, and last quarter's current intraday variation average was a positive 0.68%, a negative 0.06%, and a positive 1.24%.
ipsen's highest amplitude of average volatility was 0.68% (last week), 0.87% (last month), and 1.24% (last quarter).
more news about ipsen.
3. vetoquinol (veto.pa)
1.02% forward dividend yield and 12.13% return on equity
vetoquinol sa, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in europe, the americas, and the asia pacific region. it provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. the company was founded in 1933 and is headquartered in lure, france. vetoquinol sa is a subsidiary of soparfin sca.
earnings per share
as for profitability, vetoquinol has a trailing twelve months eps of €4.97.
pe ratio
vetoquinol has a trailing twelve months price to earnings ratio of 20.72. meaning, the purchaser of the share is investing €20.72 for every euro of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.13%.
yearly top and bottom value
vetoquinol's stock is valued at €103.00 at 06:40 est, above its 52-week high of €98.60.
dividend yield
as maintained by morningstar, inc., the next dividend payment is on jun 2, 2023, the estimated forward annual dividend rate is 0.8 and the estimated forward annual dividend yield is 1.02%.
more news about vetoquinol.